Publikation
ESG-Update
Am 16. Dezember 2022 wurde die finale Änderungsrichtlinie für die Nachhaltigkeitsberichterstattung von Unternehmen (Corporate Sustainability Reporting Directive, kurz CSRD) im Amtsblatt der Europäischen Union veröffentlicht.
We use cookies and other similar technology to collect data about you to allow us to deliver our online services, measure our website audience and improve your browsing experience. Full details on the cookies we use are set out in our Cookies policy. Please click OK to signify your consent to our use of cookies.
You can withdraw your consent by clicking “manage cookies” and following the instructions shown.
Global | Publikation | March 2016
On March 1, 2016, the U.S. Food and Drug Administration (FDA) issued guidance on screening donors of human cells, tissues, and cellular and tissue-based products for risk of evidence of infection with Zika virus. The FDA's guidance identifies Zika virus as a relevant communicable disease agent or disease (RCDAD) and provides recommendations for reducing the risk of transmission of Zika virus by human cells, tissues, and cellular and tissue-based products.
FDA regulation requires a donor-eligibility determination, based on screening and testing for RCDADs, for all donors of human cells, tissues, and cellular and tissue-based products. Such donors are eligible only if donor screening indicates that the donor is free from risk factors for and clinical evidence of infection due to RCDADs and the results of donor testing for RCDADs are negative or nonreactive.
While an FDA-licensed blood donor screening test for Zika virus is not currently available, FDA made recommendations for screening for Zika virus in living donors, birth mothers and non-heart-beating (cadaveric) donors. Living donors should be considered ineligible for donation if they have been medically diagnosed with Zika virus infection in the past six months, resided in or traveled to an area with active Zika virus transmission (as listed here by the Centers for Disease Control and Prevention) within the past six months, or had sex within the past six months with a male who is known to have either of the other two risk factors. In addition to the risk factors for living donors, birth mothers should be considered ineligible for donation of gestational tissues if they were medically diagnosed with Zika virus infection at any point during their pregnancy, resided in or traveled to an area with active Zika virus at any point during their pregnancy, or had sex at any point during their pregnancy with a male who is known to have either of the first two risk factors for living donors. Non-heart-beating (cadaveric) donors should be considered ineligible if the person had a medical diagnosis of Zika virus infection in the past six months.
FDA recommends implementing these recommendations as soon as feasible, but no later than March 29, 2016. Now that the Zika virus has been classified as an RCDAD, all licensed establishments making donor eligibility determinations should incorporate these recommendations into their standard operating procedures, as necessary.
*Wendy Wright is admitted only in North Carolina. Her practice is supervised by principals of the firm admitted in the District of Columbia.
Publikation
Am 16. Dezember 2022 wurde die finale Änderungsrichtlinie für die Nachhaltigkeitsberichterstattung von Unternehmen (Corporate Sustainability Reporting Directive, kurz CSRD) im Amtsblatt der Europäischen Union veröffentlicht.
Subscribe and stay up to date with the latest legal news, information and events...
© Norton Rose Fulbright LLP 2023